"A new consumer-friendly form ( is now available for making reports to MedWatch, the Food and Drug Administration's (FDA) on-line system for collecting information about serious problems with drugs, medical devices and other FDA-"...
Deaths or serious or severe adverse events attributed to Prussian blue insoluble have not been reported. Constipation was reported in 10/42 (24%) patients in the Goiânia accident treated with Prussian blue insoluble. Severity of constipation was mild in 7 patients and moderate in 3 patients. Constipation was successfully treated with a high fiber diet.
Undefined gastric distress was reported in 3 patients treated with 20 gram/day of Prussian blue insoluble. In these patients the dose was reduced to 10 gram/day for continued treatment.
Read the Radiogardase (insoluble prussian blue) Side Effects Center for a complete guide to possible side effects
Adequate and well-controlled drug-drug interaction studies in humans were not identified in the literature. In preliminary studies, animals were contaminated with several different radioisotopes and treated with several different radioeliminators. Based on these animal data, co-administration of Prussian blue with other radioeliminators does not affect the efficacy of Prussian blue for 137Cs.
Binding to some therapeutic drugs and essential nutrients is possible. The literature contains anecdotal reports of asymptomatic hypokalemia and decreased bioavailability of oral tetracycline. The serum levels and, or clinical response to critical orally administered products should be monitored.
Read the Radiogardase Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 10/1/2008
Additional Radiogardase Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.